| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Nexalin Technology, Inc.$0.47
-0.01 (-2.28%)
Market Cap
7.77 M
EPS
-0.46
P/E Ratio
-
Value Trade
83.28 K
SEC Financials
Q1 2026Dilution Risk
Revenue
14.95 K
R&D Expenses
346.38 K
Operating CF
-1.71 M
Total Assets
3.69 M
Total Liabilities
808.36 K
Equity
2.89 M
D/E Ratio
12,345
14.45 %
Week
-13.17 %
1 Month
-19.12 %
3 Month
-62.23 %
6 Month
-86.01 %
5 Year
-86.01 %
All Time
Cash Data
Cash Position
2.71 M
Monthly Burn
571.00 K
Runway
2.3 mo
Burn Trend
SEC Filing
May 8, 2026
Overview
Volume
121.45 K
52 Week Range
0.31 - 2
% held by Insiders
19.1 %
% held by Institutions
4.84 %
Enterprise Value
5.07 M
Total Shares
20.57 M
Short %
3.04 %
Float Shares
16.46 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Nexalin DIFS™ | insomnia and anxiety | — | 2026-06-23 | significant improvement in sleep quality as measured by the Pittsburgh Sleep Quality Index (PSQI), observed both at the end of treatment and at follow-up, with large effect sizes Read More | Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform Read More | |
Nexalin DIFS™ | insomnia and anxiety | — | 2026-06-23 | significant improvement in sleep quality as measured by the Pittsburgh Sleep Quality Index (PSQI), observed both at the end of treatment and at follow-up, with large effect sizes Read More | Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform Read More | |
Nexalin DIFS™ | insomnia and anxiety | — | 2026-06-23 | significant improvement in sleep quality as measured by the Pittsburgh Sleep Quality Index (PSQI), observed both at the end of treatment and at follow-up, with large effect sizes Read More | Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NXL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NXL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NXLNexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform
Nexalin Technology announced that Dr. Victor Fontenelle Bastos de Lima received the Young Researcher Award at BRAIN 2026 for his research on the DIFS™ platform. The study demonstrated significant improvements in sleep quality among patients with insomnia and anxiety. This recognition enhances Nexalin's credibility as it prepares for a product launch in Brazil.
Read more →NXLNexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform
Nexalin Technology announced that Dr. Victor Fontenelle Bastos de Lima received the Young Researcher Award at BRAIN 2026 for his research on the DIFS™ platform. The study demonstrated significant improvements in sleep quality among patients with insomnia and anxiety. This recognition bolsters Nexalin's credibility as it prepares to launch its product in Brazil.
Read more →NXLNexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life
Nexalin Technology has announced the acceptance of two clinical abstracts for presentation at the 2026 NYC Neuromodulation Conference. The abstracts highlight positive preliminary results from their DIFS™ treatment platform, showing significant improvements in anxiety, depression, insomnia, and quality of life. The data demonstrate a high response rate and sustained benefits, reinforcing the platform's scientific viability.
Read more →NXLNexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.
Nexalin Technology announced positive results from a clinical trial in Brazil, demonstrating a 77.8% anxiety response rate and significant improvements in depression and insomnia. The trial, which involved 20 sessions of neurostimulation, showed durable benefits maintained at an 8-week follow-up. The results support Nexalin's non-invasive treatment approach and its plans for a product launch in Brazil.
Read more →NXLNexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia
Nexalin Technology has announced the issuance of a U.S. patent for its dynamic frequency stimulation method, aimed at treating anxiety, depression, and insomnia. This patent will provide intellectual property protection until 2042, reinforcing Nexalin's competitive edge in non-invasive neurostimulation. The company believes this technology can significantly improve mental health treatment options and is central to its strategic initiatives.
Read more →NXL▲ +19.1%on this news· ran to +67% by day 3
Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury
Nexalin Technology, Inc. has secured a significant legislative provision from the U.S. House Appropriations Committee that directs the Department of Veterans Affairs (VA) to support research into non-invasive deep brain neurostimulation technologies for veterans suffering from treatment-resistant traumatic brain injury (TBI). This favorable report language comes as part of the Fiscal Year 2027 Appropriations bill, which has passed the House with overwhelming support. The inclusion indicates a growing recognition of the potential benefits of Nexalin's DIFS™ technology and aims to distinguish it from traditional stimulation methods.
Read more →NXLNexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial
Nexalin Technology, Inc. has acquired PONM, Inc., enhancing its HALO™ Clarity program with AI-integrated digital health capabilities. This acquisition allows Nexalin to manage remote patient monitoring and clinical data workflows more effectively. The platform is already in use at UCSD and will support Nexalin's upcoming pivotal trial for insomnia treatment, expected to begin in Q2 2026.
Read more →NXLNexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial
Nexalin Technology, Inc. has acquired PONM, Inc., enhancing its HALO™ Clarity program with AI-integrated digital health capabilities. This acquisition allows Nexalin to control critical software features for remote patient monitoring and clinical data management, supporting its upcoming pivotal trial for moderate-to-severe insomnia. The partnership with GreenLight Ventures further strengthens Nexalin's resources and strategic position.
Read more →NXLNexalin Acquires AI-Integrated Digital Health Platform Behind HALO Clarity and Nexalin NeuroCare Ahead of Planned FDA Pivotal Trial Acquisition gives Nexalin control of AI-integrated remote patient-
Nexalin Technology, Inc. has completed its acquisition of PONM, Inc., a digital health platform that supports the HALO Clarity program and Nexalin NeuroCare virtual clinic. This acquisition grants Nexalin control over essential AI-integrated technologies for remote patient monitoring and clinical data capture. The technology, already deployed at UCSD, is expected to enhance treatment oversight for an upcoming pivotal trial for HALO Clarity. Nexalin's strategy aims to leverage the integrated platform for efficient regulatory submission and commercialization of its at-home therapy solutions.
Read more →NXL▼ -8.6%on this news
Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia
Nexalin Technology, Inc. announced the publication of a peer-reviewed study demonstrating significant clinical improvement in chronic insomnia patients treated with its DIFS™ technology. The study reported a notable reduction in Pittsburgh Sleep Quality Index scores for the active treatment group compared to the sham group. Neuroimaging data provided mechanistic insights into how the treatment modulates brain networks associated with sleep quality.
Read more →NXL▲ +7.7%on this news
Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment
Nexalin Technology has announced the advancement of its pivotal clinical trial for the HALO™ Clarity device, targeting moderate-to-severe insomnia, with patient enrollment expected to begin in Q2 2026. The trial, involving 160 participants, aims to support a De Novo Classification Request to the FDA, potentially establishing a new product category. Collaboration with Lindus Health is expected to enhance trial execution, while the company anticipates significant market opportunities in the insomnia treatment space.
Read more →NXL▲ +7.7%on this newsshared move
Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment
Nexalin Technology, Inc. has announced the advancement of its pivotal clinical trial for the HALO™ Clarity device aimed at treating moderate-to-severe insomnia, with enrollment targeted to start in Q2 2026. This trial, which will involve 160 participants and is structured as a randomized, triple-blinded, sham-controlled study, supports the company’s De Novo Classification Request to the FDA. The initiative is bolstered by previous clinical data indicating positive results, and is expected to play a crucial role in establishing HALO™ Clarity as a unique neurostimulator in the mental health sector. Collaboration with Lindus Health is set to enhance the trial's execution and regulatory processes as Nexalin progresses toward key milestones.
Read more →NXL▲ +7.7%on this newsshared move
Technology Advances Pivotal Clinical Trial of HALO Clarity
Nexalin Technology, Inc. has announced the advancement of its pivotal clinical trial for the HALO Clarity device aimed at treating moderate-to-severe insomnia, with patient enrollment projected to begin in Q2 2026. This randomized and triple-blinded study is designed to support a De Novo FDA submission, potentially establishing a new product category for the HALO Clarity device. Nexalin's collaboration with Lindus Health aims to ensure rigorous trial execution and supports broader goals in insomnia treatment. Previous peer-reviewed data indicates positive treatment outcomes, bolstering the clinical case for this innovative approach to mental health.
Read more →NXL▲ +18.4%on this news
Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and China
Nexalin Technology, Inc. has completed key meetings in the U.S. and China to advance its clinical strategy for treating Alzheimer's disease. The FDA provided guidance for the company's upcoming De Novo application, focusing on clinical trial design. Insights from these discussions will shape Nexalin's regulatory strategy and clinical trial endpoints. The company aims to lead in non-invasive treatments for cognitive decline.
Read more →NXL▲ +18.4%on this newsshared move
Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and China
Nexalin Technology, Inc. has announced the successful completion of important meetings in the U.S. and China to advance its clinical strategy for Alzheimer's disease treatment. These discussions included a productive interaction with the FDA, which provided guidance on clinical trials. As a result, Nexalin is set to amend its Q-Submission application in Q2 2026. The collaboration with Professor Yi Tang in China brings valuable clinical insights which will inform Nexalin's approach to addressing cognitive decline in Alzheimer's patients.
Read more →NXLJoin Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21
Nexalin Technology, Inc. will host an investor webinar on April 21, 2026, featuring CEO Mark White. The session will discuss the company's DIFS technology, clinical evidence, and product developments, including the Gen-3 HALO Clarity headset. The event aims to highlight Nexalin's pathway to global commercialization in mental health treatment.
Read more →NXLJoin Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21
Nexalin Technology, Inc. will host an investor webinar on April 21, 2026, featuring CEO Mark White. The session will cover Nexalin's unique approach to mental healthcare using its Deep Intracranial Frequency Stimulation (DIFS) technology, along with updates on its product portfolio and regulatory advancements. A Q&A session will follow the presentation.
Read more →NXL▲ +8.6%on this news· ran to +23% by day 3shared move
Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents
Nexalin Technology, Inc. announced a peer-reviewed study published in BMC Psychiatry, demonstrating that its DIFS™ technology significantly reduced self-injury behaviors and depressive symptoms in female adolescents. The study involved six patients who underwent 21 days of stimulation, showing lasting improvements and changes in brain connectivity. The findings support the potential of DIFS as a non-invasive treatment for mental health disorders.
Read more →NXL▲ +8.6%on this news· ran to +23% by day 3shared move
Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents
Nexalin Technology, Inc. announced a peer-reviewed study published in BMC Psychiatry, demonstrating that its DIFS technology significantly reduces self-injury behaviors and depressive symptoms in female adolescents. The study involved six patients who underwent 21 days of treatment, showing lasting improvements and changes in brain connectivity. This research adds to Nexalin's growing body of evidence supporting its non-invasive neurostimulation approach.
Read more →NXL▲ +15.1%on this news
Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market
Nexalin Technology, Inc. has announced a pivotal clinical trial for HALO™ Clarity, aimed at treating moderate to severe insomnia. The study, in collaboration with Lindus Health, will enroll 150 participants and is designed to support a de novo FDA submission. This trial builds on previous positive clinical data and aims to address the significant insomnia market, which lacks effective drug-free treatments.
Read more →NXL▲ +15.1%on this newsshared move
Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market
Nexalin Technology, Inc. has announced a pivotal clinical trial for HALO™ Clarity, aimed at treating moderate to severe insomnia. The study, involving 150 participants, will support the company's de novo FDA submission. Conducted in collaboration with Lindus Health, the trial will utilize a decentralized approach, allowing remote participation. This initiative builds on previous clinical data and targets a significant market opportunity in insomnia treatment.
Read more →NXLNexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders
Nexalin Technology, Inc. has praised recent bipartisan Congressional initiatives aimed at enhancing federal support for deep brain neurostimulation research, particularly for veterans. The company's DIFS™ technology is highlighted as a promising treatment for conditions such as TBI and PTSD. Nexalin's advocacy efforts have contributed to legislative provisions that could expand access to innovative therapies for veterans.
Read more →NXL▲ +9.2%on this news
Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer’s, Mood Disorders, TBI & PTSD Care
Nexalin Technology, Inc. has launched NeuroCare®, an AI-driven virtual clinic designed to improve access to treatment for patients with Alzheimer’s, mood disorders, TBI, and PTSD. This platform integrates with Nexalin's Gen-3 HALO™ headset, allowing for remote monitoring and care. The initiative aims to reduce costs and stigma associated with traditional psychiatric care while enhancing long-term patient outcomes.
Read more →NXL▲ +9.2%on this newsshared move
Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer’s, Mood Disorders, TBI & PTSD Care
Nexalin Technology, Inc. has launched its AI-driven virtual clinic platform, NeuroCare®, in collaboration with UC San Diego. This initiative aims to improve access to treatment for patients with Alzheimer’s, mood disorders, TBI, and PTSD. The platform integrates Nexalin’s Gen-3 HALO headset for remote monitoring and aims to reduce costs and stigma associated with traditional psychiatric care.
Read more →NXLNexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation
Nexalin Technology, Inc. has highlighted its peer-reviewed research validating its DIFS™ neurostimulation technology for various neurological and psychiatric conditions. The company is advancing its clinical business plan with the FDA, showcasing data that demonstrates objective normalization of brain activity. Recent studies indicate significant improvements in brain function and patient outcomes, positioning Nexalin as a leader in non-invasive brain stimulation.
Read more →NXLNexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation
Nexalin Technology, Inc. has highlighted its peer-reviewed research validating its DIFS™ technology for treating various neurological and psychiatric conditions. The studies show objective improvements in brain function and symptom relief across multiple disorders, including ADHD, PTSD, and depression. Nexalin aims to advance its clinical business plan with the FDA, emphasizing its unique ability to penetrate deep brain networks.
Read more →NXLTechnology Receives Nasdaq Listing Status Notification
Nexalin Technology, Inc. (NASDAQ: NXL) has received a notification from NASDAQ indicating non-compliance with the minimum bid price requirement of $1.00 per share, with a compliance deadline until July 20, 2026. The company has been given 180 calendar days to regain compliance, during which its shares will continue to trade uninterrupted. Nexalin is actively monitoring its bid price and considering various measures to enhance its financial position, although it does not plan any reverse stock split at this time.
Read more →NXLNexalin Technology Receives Nasdaq Listing Status Notification
Nexalin Technology, Inc. has received a notification from NASDAQ indicating it does not comply with the minimum bid price requirement. The company has until July 20, 2026, to regain compliance by maintaining a bid price of at least $1.00 per share for 10 consecutive trading days. While this notification does not have an immediate effect on trading, it poses a risk of delisting if the company fails to take corrective measures. Nexalin is exploring various strategies to improve its financial position.
Read more →NXL▲ +8.1%on this news
Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD
Nexalin Technology, Inc. announced a peer-reviewed study showing that its Deep Intracranial Frequency Stimulation (DIFS™) technology significantly improves attention and normalizes brain activity in adults with ADHD. The study, published in Molecular Psychiatry, demonstrated measurable changes in brain function and a reduction in ADHD symptoms, validated through advanced neuroimaging techniques. The treatment was well tolerated with no serious adverse events reported.
Read more →NXL▲ +8.1%on this newsshared move
Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD
Nexalin Technology, Inc. announced the publication of a peer-reviewed study demonstrating that its Deep Intracranial Frequency Stimulation (DIFS™) technology significantly improves attention and normalizes brain activity in adults with ADHD. The study showed measurable improvements in brain function and ADHD symptoms, validated by advanced neuroimaging techniques. The treatment was well tolerated and exhibited a favorable safety profile.
Read more →NXLHARNESSING THE POWER OF ADVANCED FREQUENCY NEUROSTIMULATION TO IMPROVE MENTAL HEALTH INVESTOR PRESENTATION | DECEMBER 2025 NASDAQ: NXL
Nexalin Technology, Inc. has presented its advanced neurostimulator technology called Deep Intracranial Frequency Stimulation (DIFS), aimed at improving mental health treatments. DIFS reportedly offers greater efficacy compared to existing therapies and is designed to be non-invasive with no associated patient discomfort. The company highlights the potential of its technology to reset brain networks and influence neurotransmitter production. However, they acknowledge the uncertainties involved with capital requirements and the success of ongoing clinical trials, which could affect future performance.
Read more →NXLNexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program
Nexalin Technology has successfully completed a Q-Submission meeting with the FDA regarding its Gen-2 SYNC neurostimulation console aimed at treating Alzheimer's disease. The meeting focused on the clinical development plan and regulatory strategy, discussing the potential use of the De Novo classification pathway. Nexalin plans to incorporate FDA feedback into its upcoming clinical protocol and Investigational Device Exemption submission.
Read more →NXLNexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program
Nexalin Technology has successfully completed its Q-Submission meeting with the FDA for its Gen-2 SYNC neurostimulation console aimed at treating Alzheimer's disease. The meeting established a clear path for clinical development and regulatory strategy, including discussions about using the De Novo classification pathway. Key endpoints for clinical trials were defined, which align with the company’s plans for pilot and pivotal studies. The feedback received from the FDA will be instrumental in finalizing the upcoming clinical protocols and submissions.
Read more →NXL▲ +5.4%on this newsshared move
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4
Nexalin Technology, Inc. is hosting a live investor webinar on December 4, 2025, featuring CEO Mark White. The session will cover Nexalin's proprietary Deep Intracranial Frequency Stimulation technology and its clinical evidence, including partnerships with notable institutions. The company is expanding its presence in the mental health market, which is valued at $537 billion.
Read more →NXLNexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity
Nexalin Technology, Inc. announced promising results from an independent study published in The American Journal on Addictions, evaluating its 15 milliamp neurostimulation device in treating gambling disorders with comorbid alcohol use disorders. The study, which involved 20 outpatient treatment sessions, reported that the patient achieved complete abstinence from both gambling and alcohol with marked cognitive improvements after treatment. The findings suggest a potential breakthrough in non-invasive addiction treatment, warranting further controlled trials to assess the device's efficacy across broader patient populations.
Read more →NXL▼ -7.1%on this newsshared move
Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel
Nexalin Technology, Inc. has appointed Carmi Masha Technologies Ltd. as its exclusive distributor in Israel for its non-invasive SYNC device, following regulatory approval for its sale in the country. The collaboration aims to market the device for treating mental health disorders, including insomnia, depression, and anxiety. Both companies are also looking into future applications of the device for various severe conditions like PTSD and Alzheimer's disease. This partnership marks a strategic step in expanding Nexalin's presence in international markets, particularly across the Middle East.
Read more →NXLNexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia
Nexalin Technology announced that the FDA has accepted its Q-Submission for the Gen-2 SYNC system aimed at treating Alzheimer's disease and dementia. This acceptance signifies a crucial step towards initiating U.S. clinical studies. The Q-Submission process will facilitate discussions on clinical trial design and regulatory pathways, bolstered by promising internal data and published research on the device's efficacy.
Read more →NXLNexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia
Nexalin Technology announced that the FDA has accepted its Q-Submission for the Gen-2 SYNC system aimed at treating Alzheimer's disease and dementia. This acceptance allows for structured dialogue with the FDA regarding clinical trial design and regulatory pathways. The company has reported encouraging internal data supporting the efficacy and safety of its non-invasive neurostimulator, which could significantly impact cognitive disorders.
Read more →NXLNexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel
Nexalin Technology has received regulatory approval for its Gen-2 SYNC neurostimulation device in Israel. This approval marks a significant milestone for the company, allowing it to expand its presence in international markets. CEO Mark White emphasized the importance of this clearance in enhancing the credibility of their drug-free technology for treating mental health disorders.
Read more →NXLNexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel
Nexalin Technology has received regulatory approval for its Gen-2 SYNC neurostimulation device in Israel. This approval marks a significant milestone for the company, allowing it to introduce its innovative, drug-free technology to the Israeli market. The CEO emphasized the importance of this clearance in enhancing global credibility and expanding their presence in international markets.
Read more →NXL▼ -8.3%on this news
Nexalin’s DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed Studies
Nexalin Technology, Inc. announced positive results from three peer-reviewed studies on its DIFS™ neurostimulation technology for Alzheimer's disease. The studies showed significant improvements in cognitive function and brain connectivity. This non-invasive approach may provide a safer and more effective alternative to traditional drug therapies, which often have limited benefits and safety concerns.
Read more →NXL▼ -8.3%on this newsshared move
Nexalin’s DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed Studies
Nexalin Technology, Inc. announced positive results from three peer-reviewed studies on its DIFS™ technology for treating Alzheimer's disease. The studies showed significant cognitive improvements and enhanced brain connectivity in patients. This non-invasive approach offers a promising alternative to traditional drug therapies, which often have limited efficacy and safety concerns.
Read more →NXLNexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer’s and Traumatic Brain Injury Programs
Nexalin Technology has appointed Dr. Robert Rothstein to its Scientific Advisory Board to enhance its focus on Alzheimer's disease and Traumatic Brain Injury (TBI). Dr. Rothstein's extensive experience in mental healthcare will support the company's upcoming FDA submissions. Nexalin aims to initiate Alzheimer's trials in Q4 2025, leveraging its innovative DIFS™ technology.
Read more →NXLNexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer’s and Traumatic Brain Injury Programs
Nexalin Technology has appointed Dr. Robert Rothstein to its Scientific Advisory Board to enhance its focus on Alzheimer's disease and Traumatic Brain Injury (TBI). Dr. Rothstein brings extensive experience in mental healthcare and will assist in preparing for upcoming FDA submissions. The company aims to initiate Alzheimer's trials in Q4 2025 and is intensifying its research efforts in neuropsychiatric therapeutics.
Read more →NXL▼ -14.7%on this newsshared move
Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit
Nexalin Technology, Inc. will attend the 2025 Maxim Growth Summit on October 22nd at The Hard Rock Hotel NYC. The event will feature industry experts discussing advancements in various sectors. Attendees can interact with Nexalin's management to learn about their non-invasive neurostimulation treatment aimed at addressing mental health issues globally.
Read more →NXL▲ +98.3%on this newsshared move
Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer’s Disease with Gen-2 SYNC Neurostimulation Device
Nexalin Technology has announced positive clinical results for its Gen-2 SYNC neurostimulation device, demonstrating significant cognitive improvements in Alzheimer's patients. The study published in Radiology provides strong evidence for the device's efficacy as a non-invasive treatment. This advancement supports Nexalin's strategy to offer alternatives to traditional pharmacologic treatments in a growing market.
Read more →NXL▲ +98.3%on this newsshared move
Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer’s Disease with Gen-2 SYNC Neurostimulation Device
Nexalin Technology announced positive clinical results for its Gen-2 SYNC neurostimulation device in treating mild Alzheimer's disease. The study, published in Radiology, demonstrated significant cognitive improvements and enhanced brain connectivity without adverse effects. This non-invasive treatment shows promise as an alternative to pharmacological options in the growing Alzheimer's market.
Read more →NXL▼ -6%on this news
Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology
Nexalin Technology has announced the issuance of a U.S. Design Patent for its HALO™ Clarity device, which utilizes Deep Intracranial Frequency Stimulation (DIFS™) technology. This device aims to provide non-invasive treatment for mental health conditions, including Alzheimer's, and is designed for supervised at-home use. The patent enhances Nexalin's intellectual property and supports ongoing clinical initiatives, with multiple studies underway to evaluate its efficacy.
Read more →NXL▼ -6%on this newsshared move
Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology
Nexalin Technology has received a U.S. Design Patent for its HALO™ Clarity device, which utilizes Deep Intracranial Frequency Stimulation (DIFS™) technology. This device aims to provide non-invasive treatment for mental health issues, allowing patients to receive therapy at home under clinician supervision. The patent enhances Nexalin's intellectual property portfolio and supports ongoing clinical studies across various indications.
Read more →NXL▼ -18.2%on this news
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on September 9
Nexalin Technology, Inc. is hosting a live investor webinar on September 9, 2025, to discuss its innovative Deep Intracranial Frequency Stimulation (DIFS™) technology. CEO Mark White will present clinical evidence and updates on the Gen-3 HALO™ Clarity headset, emphasizing the company's growth in the mental health market. A Q&A session will follow the presentation.
Read more →NXL▼ -18.2%on this newsshared move
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on September 9
Nexalin Technology, Inc. is hosting a live investor webinar on September 9, 2025, to discuss its innovative Deep Intracranial Frequency Stimulation (DIFS) technology for mental healthcare. CEO Mark White will present clinical evidence and updates on the Gen-3 HALO Clarity headset. The company aims to expand its presence in the growing mental health market, valued at $537 billion.
Read more →NXLNexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet
Nexalin Technology has appointed Justin Van Fleet as Chief Financial Officer as it prepares for its next phase of growth. Van Fleet brings over 20 years of experience in public accounting and financial strategy, which includes advising companies on complex transactions. His expertise is expected to support Nexalin's innovative neurostimulation platform, which is currently under FDA review for treating various mental health conditions. The leadership believes that these advancements can lead to significant improvements in patient care.
Read more →NXLNexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin’s Next Phase of Growth and Strategic Initiatives
Nexalin Technology has appointed Justin Van Fleet as CFO, effective August 1, 2025. With over 20 years of experience in public accounting, Van Fleet will oversee the company's financial strategy as it advances its neurostimulation devices through regulatory review. His expertise is expected to support Nexalin's growth and innovation in treating mental health conditions.
Read more →NXLNexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin’s Next Phase of Growth and Strategic Initiatives
Nexalin Technology has appointed Justin Van Fleet as CFO, effective August 1, 2025. With over 20 years of experience in public accounting, he will oversee the company's financial strategy as it advances its neurostimulation devices through regulatory review. The appointment comes at a crucial time as Nexalin aims to scale operations and enhance its offerings in mental health treatment.
Read more →NXLJoin Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on June 3
Nexalin Technology, Inc. invites investors to a webinar on June 3, 2025, showcasing its innovative Deep Intracranial Frequency Stimulation technology. CEO Mark White will discuss clinical evidence, updates on the Gen-3 HALO Clarity headset, and the company's expansion in the mental health market. The session will include a live Q&A for attendees.
Read more →NXLNexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging Data
Nexalin Technology, Inc. has reconstituted its Scientific Advisory Board with three experts in neurology and neuroimaging to enhance its Alzheimer’s program. This strategic move aims to leverage their expertise in guiding clinical trials and research efforts focused on Alzheimer’s and neurodegenerative diseases. The company aims to initiate Alzheimer’s-focused clinical studies in the third quarter of 2025, incorporating various innovative methodologies to assess treatment efficacy.
Read more →NXL▼ -5.3%on this news
Nexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public Offering
Nexalin Technology, Inc. announced the successful closure of its previously disclosed underwritten public offering, raising approximately $5 million through the sale of 3,850,000 shares at $1.30 each. The offering was conducted under the effective shelf registration statement previously filed with the SEC. This capital infusion aims to support the company’s development of neurostimulation products designed to combat mental health issues. Nexalin emphasizes its commitment to non-invasive solutions that target deeper brain structures associated with mental health disorders.
Read more →NXL▼ -25.7%on this newsshared move
Nexalin Technology Announces Pricing of $5.0 Million Public Offering of Common Stock HOUSTON, TX
Nexalin Technology, Inc. announced the pricing of a public offering involving 3,850,000 shares of common stock at $1.30 each, aiming to raise approximately $5.0 million. The offering is expected to close around May 6, 2025, pending customary conditions. Maxim Group LLC is managing the offering which will support the company's working capital and product development endeavors. Additionally, a shelf registration statement for the shares was filed and has been approved by the SEC.
Read more →NXLNexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback
Nexalin Technology has announced its plan to initiate a Q-Submission process with the FDA for its Gen-2 SYNC system, aimed at treating Alzheimer’s disease, dementia, and mild cognitive impairment. This regulatory step is supported by recent encouraging internal data and preliminary feedback from the FDA. The Gen-2 SYNC system features technical upgrades from previous models and represents a significant strategy shift as the company seeks FDA alignment on clinical trial design. Nexalin's focus remains on advancing non-invasive therapeutic options for neuropsychiatric disorders.
Read more →NXL▲ +5.7%on this news
Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia
Nexalin Technology, Inc. has announced that its Gen-2 neurostimulation device received IRB approval in Brazil, allowing the company to commence a Phase II clinical trial aimed at treating anxiety and chronic insomnia. The trial will be conducted at one of Latin America's leading psychiatric research institutions and will involve 30 adult patients. This marks a significant step in Nexalin's international strategy to evaluate its neurostimulation technology in new markets. Results from the trial are anticipated to be published in a peer-reviewed journal.
Read more →NXLNexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management
Nexalin Technology has successfully completed phases one through five of its virtual clinic and digital ecosystem, enhancing its capabilities for clinical research and patient management. The platform, launched at UCSD, supports real-time data capture and remote monitoring for patients using the HALO™ headset. This advancement positions Nexalin to expand research collaborations and accelerate commercialization efforts for its non-invasive DIFS™ technology.
Read more →NXLNexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management
Nexalin Technology has announced the completion of phases one through five of its virtual clinic and digital ecosystem, aimed at enhancing clinical research and patient management for its HALO™ technology. The launch, conducted at the University of California, San Diego, will assist in recruiting patients for studies focused on traumatic brain injury and PTSD. The integrated system includes AI-powered data capture and remote patient monitoring capabilities, allowing for real-time oversight and compliance validation. This development positions Nexalin for further research collaborations and potential commercialization of its treatments.
Read more →NXLNexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices
Nexalin Technology has expressed strong support for the Health Tech Investment Act, a bipartisan effort in the U.S. Senate aimed at expanding Medicare reimbursement for AI-driven medical devices. The proposed legislation would facilitate timely reimbursement for such technologies, allowing for data collection and long-term assessment of their efficacy. Nexalin's anticipated Gen-3 HALO Clarity™ device, designed for mental health treatment, exemplifies the intended advancements highlighted by the Act. With a focus on non-invasive neurostimulation and AI, Nexalin aims to enhance care delivery in an evolving digital healthcare landscape.
Read more →NXLNexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders
Nexalin Technology has received a patent from the USPTO for its Deep Intracranial Frequency Stimulation (DIFS™) technology, aimed at treating substance use disorders. This non-invasive method targets neural pathways associated with addiction, potentially improving treatment outcomes. The patent reinforces Nexalin's commitment to innovative, drug-free solutions in mental health therapy.
Read more →NXLNexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders
Nexalin Technology, Inc. has announced the granting of a patent by the USPTO for its Deep Intracranial Frequency Stimulation (DIFS™) technology aimed at treating substance use disorders, including opioid use disorder and alcohol use disorder. This patent is positioned to enhance Nexalin's intellectual property portfolio and underscores the potential of DIFS as a non-invasive, drug-free alternative for individuals struggling with addiction. The technology seeks to regulate neural pathways associated with addiction and may alleviate withdrawal symptoms, offering a unique approach in mental health therapy. The announcement highlights Nexalin's commitment to pioneering innovative treatment solutions for addiction and mental health challenges.
Read more →NXL▲ +5.8%on this news
Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial
Nexalin Technology has enrolled the first patients in its clinical trial at UCSD, utilizing the HALO™ Clarity device to treat mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD). This milestone signifies the start of active patient participation in a study that aims to evaluate the efficacy of Nexalin’s proprietary Deep Intracranial Frequency Stimulation (DIFS™). The collaboration with the University of California, San Diego and the San Diego VA aims to develop innovative solutions for veterans and civilians facing mental health challenges. Results from this clinical trial will inform Nexalin's future regulatory and commercialization strategies.
Read more →NXLJoin Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3
Nexalin Technology, Inc. is hosting a live investor webinar on April 3, 2025, featuring CEO Mark White. The session will cover the company's clinical data on its non-invasive brain stimulation device and the new Gen-3 HALO™ Clarity model. The event aims to engage investors and share insights into Nexalin's growth in the mental health treatment market.
Read more →NXL▼ -10.7%on this news
Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders
Nexalin Technology, Inc. has received a Notice of Allowance from the USPTO for its patent on Deep Intracranial Frequency Stimulation (DIFS) technology. This non-invasive method aims to treat substance use disorders, including opioid addiction, by modulating neural pathways. The patent enhances Nexalin's position as a leader in innovative medical solutions for addiction treatment.
Read more →NXL▼ -10.7%on this newsshared move
Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders
Nexalin Technology has received a Notice of Allowance from the USPTO for its patent on Deep Intracranial Frequency Stimulation (DIFS™), aimed at treating opioid use disorder and other substance use disorders. The DIFS technology is a non-invasive, drug-free method that seeks to modulate neural pathways related to addiction, offering a new avenue for treatment. CEO Mark White emphasized the patent as a significant milestone in addressing urgent healthcare challenges posed by substance use disorders. With this advancement, Nexalin strengthens its role in the development of innovative solutions that could redefine standards in addiction treatment.
Read more →NXLNexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval
Nexalin Technology has announced the initiation of patient recruitment for a clinical study at UCSD, following IRB approval. The study will evaluate the HALO Clarity device, which utilizes non-invasive Deep Intracranial Frequency Stimulation (DIFS) technology to treat mild traumatic brain injury (mTBI) and PTSD. This marks a significant step in validating Nexalin's innovative approach to neurostimulation.
Read more →NXLNexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval
Nexalin Technology has announced the initiation of patient recruitment for a clinical study at UCSD, aimed at evaluating its HALO Clarity device for treating mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD). Following Institutional Review Board approval, the company will utilize its proprietary Deep Intracranial Frequency Stimulation (DIFS) technology, which provides a non-invasive treatment approach. Initial shipments of the HALO devices have been delivered, and these will be monitored through Nexalin's advanced electronic systems. The study marks a significant step in validating Nexalin's innovative neurostimulation technologies.
Read more →NXL▲ +7.6%on this newsshared move
Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board
Nexalin Technology has appointed General Wesley K. Clark to its Military & Government Advisory Board. This strategic move aims to enhance the company's neurostimulation solutions for mental health issues within the U.S. military and government sectors. General Clark's extensive military experience will support the Nexalin America initiative, which addresses conditions like PTSD and traumatic brain injury.
Read more →NXL▲ +7.6%on this newsshared move
Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board
Nexalin Technology, Inc. has announced the appointment of General Wesley K. Clark to its Military & Government Advisory Board. General Clark will work alongside key figures to advance Nexalin's neurostimulation solutions aimed at addressing mental health conditions in military personnel. The company's 'Nexalin America' initiative seeks to combat issues like PTSD, traumatic brain injury, and substance use disorder. Clark's leadership experience is expected to profoundly impact the integration of Nexalin's technology into U.S. military healthcare initiatives.
Read more →NXLInside Nexalin: CEO Mark White on TBI Solutions & Expanding Market Potential
Nexalin Technology announced that the investigator of its Brazilian clinical trial received the Young Researcher Award at BRAIN 2026. This recognition underscores the significance of the company's proprietary DIFS™ platform in the field. The award reflects the promising advancements being made in the clinical trial.
Read more →NXLNexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment
Nexalin Technology, Inc. has received Institutional Review Board (IRB) approval from UCSD for clinical trials utilizing its HALO Clarity headset to treat mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD). The study, independently conducted by UCSD, will involve the use of 50 HALO devices, which Nexalin is providing for research purposes. The HALO technology offers a non-invasive, drug-free treatment option and integrates advanced monitoring capabilities, including telemedicine and AI-driven patient care. This milestone is anticipated to generate essential data to validate HALO's efficacy for military personnel and others facing these conditions.
Read more →NXL▼ -5.4%on this news
Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition
Nexalin Technology, Inc. has been appointed as Industry Co-Chair of the National Traumatic Brain Injury (TBI) Registry Coalition, highlighting its dedication to TBI advocacy and research. The company plans to work closely with policymakers and stakeholders to improve outcomes for individuals affected by traumatic brain injuries. In addition to this leadership role, Nexalin is engaged in a collaborative study aimed at developing innovative treatment options for veterans with TBI. The company anticipates upcoming developments to further enhance TBI care and support.
Read more →NXLNexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study
Nexalin Technology, Inc. announced a landmark study published in the Journal of Affective Disorders, demonstrating that its DIFS technology significantly reduces blood pressure in patients with major depressive disorder. The study involved 68 patients and showed notable improvements in blood pressure, particularly among those with elevated baseline levels. The treatment was well-tolerated, indicating its potential as a non-invasive solution for both mental health and cardiovascular health.
Read more →NXLNexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study
Nexalin Technology, Inc. has announced a landmark study published in the Journal of Affective Disorders, showcasing the efficacy of its Deep Intracranial Frequency Stimulation (DIFS) technology. The study found that DIFS not only provides significant reductions in blood pressure for patients with major depressive disorder but also presents a safe, non-invasive treatment option. Key findings highlighted that patients experienced measurable improvements, especially those with higher baseline blood pressure. This research paves the way for broader applications of DIFS in improving overall mental and cardiovascular health.
Read more →NXLJoin Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23
Nexalin Technology, Inc. is hosting a live investor webinar on January 23, 2025, at 4:15 p.m. ET. CEO Mark White will discuss the company's clinical data supporting its neurostimulation device and the new Gen-3 HALO™ Clarity model. The event aims to highlight Nexalin's advancements in treating mental health conditions, with a growing market projected to reach $537 billion by 2030.
Read more →NXL▲ +10.8%on this news· ran to +26% by day 3
Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025
Nexalin Technology, led by CEO Mark White, released a letter to shareholders detailing significant advancements in their mental health treatment technologies and a strategic focus for 2025. The company reported a 65% response rate in depression trials, surpassing traditional treatments, and announced plans to pursue a CE Mark for expansion into European markets. Furthermore, Nexalin is targeting various mental health disorders, including PTSD and Alzheimer’s, while leveraging AI in a virtual clinic to enhance patient care. The neuromodulation market is projected to grow significantly, positioning Nexalin for further success.
Read more →NXLNexalin Technology Completes Phase 1of its Innovative Virtual Clinic
Nexalin Technology, Inc. has launched Phase 1 of its virtual clinic, utilizing artificial intelligence and advanced data management technologies to improve the clinical trial experience for mental health treatments. The virtual clinic includes an Electronic Data Capture platform and a Patient Monitoring System, allowing for efficient real-time data analysis and patient monitoring from home. The initiative aims to enhance the use of Nexalin’s Generation 3 Halo Device, which provides non-invasive brain stimulation to address various mental health issues. With these advancements, Nexalin seeks to innovate the treatment landscape for patients struggling with mental health challenges.
Read more →NXLNew Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market
Nexalin Technology, Inc. has received validation for its Deep Intracranial Frequency Stimulation (DIFS) technology through a peer-reviewed publication in Psychotherapy and Psychosomatics. The article highlights DIFS's ability to non-invasively treat psychiatric conditions by effectively reaching deep brain regions. This positions Nexalin favorably in the expanding neuromodulation market, projected to reach $11 billion by 2028.
Read more →NXL▼ -12.1%on this news
Nexalin Technology CEO Provides Letter to Shareholders
Nexalin Technology, Inc. has released a letter from CEO Mark White highlighting recent advancements in its Deep Intracranial Frequency Stimulation (DIFS) technology for mental health and neurological conditions. Recent Alzheimer's studies show significant improvement in cognitive function and a newly issued patent enhances Nexalin's intellectual property position. The company is expanding its clinical applications through collaborations with UC San Diego and regulatory approvals in Brazil. These developments position Nexalin as a leader in innovative non-invasive treatments for Alzheimer’s and Major Depressive Disorder.
Read more →NXL▲ +17.5%on this news
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th
Nexalin Technology, Inc. is hosting a live investor webinar on November 5, 2024, featuring CEO Mark White. The event will cover the company's advancements in non-invasive neurostimulation devices and their potential impact on mental health treatment. The growing market for these solutions is projected to reach $537 billion by 2030, highlighting Nexalin's emerging leadership in the field.
Read more →NXL▲ +26.9%on this newsshared move
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
Nexalin Technology, Inc. announced that it has regained compliance with Nasdaq's minimum bid price requirements as of October 31, 2024. This milestone is viewed as crucial for the company's visibility and investor confidence as it continues its mission to develop non-invasive neurostimulation treatments for mental health disorders. CEO Mark White highlighted the significance of this achievement in driving shareholder value and thanked shareholders for their support. Nexalin's products are designed to provide relief from mental health issues using bioelectronic medical technology.
Read more →NXLNexalin Technology Announces Landmark Study on Alzheimer’s Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer’s Disease
Nexalin Technology announced the publication of a landmark study in the Journal of Alzheimer’s Disease, demonstrating the effectiveness of its Deep Intracranial Frequency Stimulation (DIFS) technology. The study involved 46 patients and showed significant improvements in neuronal activity and cognitive function in those with mild Alzheimer’s disease. Results indicated sustained cognitive benefits and enhanced brain connectivity, suggesting DIFS as a promising non-pharmacological treatment option.
Read more →NXLNexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease
Nexalin Technology announced the publication of a landmark study on the efficacy of its Deep Intracranial Frequency Stimulation (DIFS) technology for treating Alzheimer's disease. Conducted on 46 participants, the study utilized resting-state functional MRI to evaluate changes in brain activity, revealing significant increases in neuronal activity and blood flow correlated with cognitive improvement. The results indicate sustained cognitive benefits for patients post-treatment without serious side effects. This research underscores the potential of non-invasive neurostimulation as a novel approach to manage Alzheimer's disease.
Read more →NXL▲ +7.8%on this news· ran to +38% by day 3
Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA
Nexalin Technology has announced a new clinical trial for its Gen-3 Halo headset, designed for at-home treatment of mild Traumatic Brain Injury (mTBI). In collaboration with UC San Diego, the trial will evaluate the headset's effectiveness using a virtual clinic model. This approach aims to improve access to care for veterans while building on positive results from previous studies.
Read more →NXL▲ +20.9%on this news· ran to +55% by day 3shared move
Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA
Nexalin Technology, Inc. announced plans for a new clinical trial involving their Gen-3 Halo headset, developed in partnership with UC San Diego and the San Diego VA. The trial will assess the device's effectiveness for veterans suffering from mild Traumatic Brain Injury (mTBI) using a virtual clinic model for convenient treatment. It builds on encouraging results from prior studies, which indicated improvements in brain activity and relief of pain symptoms. The study aligns with the Veterans Administration's goal to enhance telehealth services for veterans.
Read more →NXL▲ +17.5%on this news· ran to +71% by day 3shared move
No More Side Effects: Nexalin’s Non-Invasive Approach to Treating Depression & PTSD
Nexalin Technology announced that the investigator of its Brazilian clinical trial received the Young Researcher Award at BRAIN 2026. This award recognizes research evaluating the company's proprietary DIFS™ platform, which aims to provide a non-invasive treatment for depression and PTSD. The acknowledgment underscores the potential impact of Nexalin's technology in mental health care.
Read more →NXL▲ +25.7%on this news· ran to +70% by day 3shared move
New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients
Nexalin Technology, Inc. announced positive results from a clinical trial of its Deep Intracranial Frequency Stimulation (DIFS) technology, showing significant improvements in memory and cognitive function in Alzheimer's patients. The study, published in Alzheimer's Research & Therapy, involved 46 patients and demonstrated notable gains in cognitive assessment scores. Functional MRI scans revealed increased neural activity and blood flow in the hippocampus, indicating the potential of DIFS in treating Alzheimer's disease.
Read more →NXL▲ +15.2%on this news· ran to +69% by day 3shared move
Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs
Nexalin Technology has appointed Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs. Shelton, with over 30 years of experience in the medical device industry, will oversee clinical studies and regulatory submissions. Her expertise is expected to aid Nexalin in pursuing global regulatory clearances and FDA Breakthrough Device designations for its innovative DIFS technology.
Read more →NXL▲ +15.2%on this news· ran to +69% by day 3shared move
Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs
Nexalin Technology has appointed Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs, highlighting her extensive experience in the medical device industry. Shelton is set to oversee clinical studies, quality systems, and regulatory submissions as the company aims for global clearances and FDA Breakthrough Device designations for its Deep Intracranial Frequency Stimulation technology. Her background includes leadership roles in regulatory and clinical strategies at various well-known organizations, making her a strategic asset for Nexalin. Both the CEO and Shelton have expressed optimism about her impact on the company's future endeavors in mental health treatment.
Read more →NXL▼ -10.3%on this news
Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment
Nexalin Technology participated in a Congressional roundtable in North Carolina discussing virtual therapeutic options for opioid treatment. Led by Congressman Greg Murphy, the event focused on the challenges of traditional in-clinic treatments and the potential for virtual therapies. Nexalin's neurostimulation technology was emphasized as an important tool for expanding access to treatment, particularly in addressing the needs of veterans. The company aims to enhance the reach of mental health care through innovative solutions that can be implemented remotely.
Read more →NXLDiscover Nexalin’s Neurostimulation Device Targeting Mental Health Disorders
Nexalin Technology announced that the investigator of its Brazilian clinical trial received the Young Researcher Award at BRAIN 2026. This recognition highlights the research evaluating the company's proprietary DIFS™ platform, which targets mental health disorders. The award underscores the potential significance of Nexalin's neurostimulation device in the field.
Read more →NXL▼ -7.4%on this news
Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery
Nexalin Technology, Inc. has been selected as a founding member of the 'Breaking Barriers to Substance Use Recovery' coalition aimed at tackling opioid use disorder in the USA. The coalition comprises leaders from various sectors, advocating for innovative treatments and policy solutions. CEO Mark White highlighted the role of Nexalin's neurostimulation technologies in potentially offering accessible treatment options, especially in underserved communities. The coalition also focuses on creating virtual solutions to enhance recovery and engagement with policymakers.
Read more →NXLNexalin Technology Announces Closing of $5.2 Million Public Offering HOUSTON
Nexalin Technology, Inc. has successfully closed its public offering of 3,000,000 shares of common stock at $1.75 per share, raising approximately $5.2 million before expenses. The offering was executed by Maxim Group LLC and was made under an SEC-approved registration statement. This capital will support Nexalin's innovative neurostimulation products designed to address mental health issues, capitalizing on bioelectronic medical technology.
Read more →NXL▲ +8.4%on this news· ran to -45% by day 3shared move
Nexalin Technology Announces Pricing of $5.2 Million Public Offering HOUSTON
Nexalin Technology, Inc. has announced a public offering of 3,000,000 shares of common stock at a price of $1.75 per share, aiming for gross proceeds of approximately $5.2 million. The offering is expected to conclude on July 1, 2024, and is being managed by Maxim Group LLC. This capital raise is positioned to support Nexalin's development of non-invasive neurostimulation products designed to alleviate mental health issues. The securities will be offered under a registration statement declared effective by the SEC.
Read more →NXL▲ +20.8%on this news· ran to +31% by day 1shared move
Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal
Nexalin Technology, Inc. announced promising results from a clinical study evaluating the efficacy of its Deep Intracranial Frequency Stimulation technology as an adjunct to escitalopram for treating major depressive disorder. The study, involving 66 participants, indicated that 66.7% of those receiving the combination therapy showed improvement, compared to only 33.3% in the sham group. This significant outcome was detailed in a publication in the journal Brain Stimulation. Additionally, no serious adverse events were recorded, supporting the safety of the combined treatment approach.
Read more →NXL▲ +5.8%on this news· ran to +117% by day 3
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia
Nexalin Technology, Inc. has received a U.S. patent for its non-invasive Deep Intracranial Frequency Stimulation (DIFS®) device aimed at treating Alzheimer’s and dementia. This patent marks a significant advancement in their technology, which utilizes a proprietary waveform for effective brain stimulation. The global market for dementia treatment is expected to grow substantially, highlighting the need for innovative solutions in mental health care.
Read more →NXL▲ +5.8%on this news· ran to +117% by day 3shared move
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia
Nexalin Technology has been awarded a key patent for its non-invasive Deep Intracranial Frequency Stimulation (DIFS®) device aimed at treating Alzheimer's and dementia. The patent, issued by the USPTO, covers the TACS method which aims to deliver effective treatment painlessly. With the global dementia treatment market projected to exceed $28 billion by 2030, Nexalin's technology addresses a critical need in mental health care, supported by substantial clinical research. CEO Mark White emphasized the potential of their device to significantly impact various neurological diseases.
Read more →NXL▲ +37.8%on this news· ran to +206% by day 3shared move
Announces Regulatory Approval to Sell Nexalin's Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency
Nexalin Technology, Inc. has received regulatory approval from the Brazilian Health Regulatory Agency to sell its Gen-2, 15 mA neurostimulation device. This marks the company's second regulatory approval outside of China in 2024, emphasizing Brazil's importance as a market. With a population of over 215 million and more than 35 million suffering from mental health disorders, Nexalin aims to leverage this approval to expand further into South America. The company is currently in discussions with potential distributors to enhance market presence.
Read more →NXL▲ +122.6%on this newsshared move
Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
Nexalin Technology has received regulatory approval from Brazil's Health Regulatory Agency for its Gen-2, 15 mA neurostimulation device. This marks the company's second regulatory approval outside of China in 2024. The approval allows Nexalin to enter a significant market with a large population affected by mental health issues, paving the way for further expansion in South America.
Read more →NXL▲ +125.1%on this newsshared move
Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
Nexalin Technology, Inc. has received regulatory approval from the Brazilian Health Regulatory Agency for its second-generation, 15 milliamp neurostimulation device. This marks Nexalin's second approval outside of China this year, highlighting Brazil's importance as a market given its large population with mental health disorders. CEO Mark White emphasized this approval as a key step in expanding the company's reach in South America, where discussions with a key distributor are advancing. The device is designed to be non-invasive and aims to address the global mental health epidemic.
Read more →NXLNexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th
Nexalin Technology, Inc. announced its participation in the Spring MicroCap Rodeo Conference on June 6, 2024, where CEO Mark White will present. The presentation will be accessible via a live webcast, allowing for wider audience engagement. The conference aims to connect investors with management teams from various MicroCap companies, providing insights into potential investment opportunities for the second half of 2024. Nexalin focuses on developing non-invasive medical devices aimed at combating mental health disorders.
Read more →NXLFDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
Nexalin Technology, Inc. announced that the FDA has reached consensus on the design for its planned clinical studies of the Gen-3 HALO Clarity™ headset aimed at treating anxiety and insomnia. The studies are set to begin in Q3 2024, involving 150 patients in total. Following the studies, Nexalin intends to submit a De Novo request to the FDA for marketing approval. The company emphasizes the potential of HALO to provide a non-invasive alternative to traditional pharmacological treatments.
Read more →NXLNexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
Nexalin Technology's division, Nexalin America, has joined the National Traumatic Brain Injury Registry Coalition, indicating a significant commitment to improving TBI research and awareness. This coalition includes notable entities like the NFL Players Association and aims to develop a national registry for traumatic brain injuries. Nexalin will leverage its expertise in neurostimulation technology to support the coalition's objectives, marking a strategic advancement in their mission to impact brain injury treatment. The partnership highlights growing recognition of technology's role in addressing TBI and improving patient outcomes.
Read more →NXLJoin Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23
Nexalin Technology, Inc. is inviting investors to a webinar on May 23, 2024, featuring CEO Mark White. The session will cover the company's clinical data on its neurostimulation device and the new Gen-3 HALO™ Clarity model. A live Q&A will follow the presentation, allowing for direct engagement with the CEO.
Read more →NXLTechn ology Regains Compliance with Nasdaq Continued Listing Requirements
Nexalin Technology, Inc. has announced its compliance with the Nasdaq minimum bid price requirement, marking a positive development for the company. CEO White highlighted the importance of this compliance for increasing investor exposure amidst ongoing positive developments. The company focuses on innovative, non-invasive technology aimed at addressing mental health conditions, with recent approvals for its neurostimulation device in both Oman and China. Nexalin is committed to its vision despite the uncertainties associated with forward-looking statements.
Read more →NXL▲ +11.4%on this news· ran to +23% by day 3
Nexalin Technology unveils positive results of clinical study for Gen-2 tACS device
Nexalin Technology has announced that the investigator of its Brazilian clinical trial has received the Young Researcher Award at BRAIN 2026. This recognition is for research evaluating the company's proprietary DIFS™ platform, which is linked to their Gen-2 tACS device. The positive results from the clinical study are expected to enhance the company's reputation in the biopharma sector.
Read more →NXLTechnology CEO Provides Letter to Shareholders
Nexalin Technology, Inc. has updated shareholders on its advancements in neurostimulation technology and the development of its Gen-3 HALO Clarity Virtual Clinic model. The company reported positive results from clinical studies indicating potential treatment benefits for conditions including PTSD and chronic insomnia. The HALO device will enable remote patient treatments, enhancing accessibility, and the company is also expanding its market presence internationally. Furthermore, Nexalin has secured regulatory approval in Oman, reflecting a strategic push towards global expansion.
Read more →NXLNexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing
Nexalin Technology has successfully completed usability, feasibility, and electrical safety testing for its Gen-3 HALO™ Clarity neurostimulation device. The company is ramping up production to support upcoming clinical trials, aiming to produce around 500 units by Q3 2024. The device's home-use capability is expected to lower treatment costs and enhance patient compliance.
Read more →NXLNexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing
Nexalin Technology, Inc. announced the successful completion of production testing for its Gen-3 HALO™ Clarity neurostimulation device. Following usability, feasibility, and safety testing, the company is ramping up production for upcoming clinical trials, aiming to produce approximately 500 units by Q3 2024. The device is designed to enable home treatment while allowing for remote monitoring by physicians. Nexalin expects these trials to be less expensive and faster than traditional methods, pending FDA approval.
Read more →NXL▼ -10.4%on this newsshared move
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
Nexalin Technology has been awarded U.S. Patent No. 17/337,653 for its Gen-3 HALO Clarity™ device, which offers non-invasive deep brain stimulation for mental health issues. This patent is a significant milestone for the company, enhancing its strategy for regulatory clearance and market rollout. The device allows patients to receive treatment at home, monitored remotely by physicians.
Read more →NXL▼ -10.4%on this newsshared move
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
Nexalin Technology has been awarded U.S. Patent No. 17/337,653 for its Gen-3 HALO Clarity™, a non-invasive deep brain stimulation device targeting anxiety, depression, and insomnia. The patent reflects a significant technological advancement and positions Nexalin strategically with support from new clinical data. With the Gen-3 system enabling remote treatments, the company aims to enhance patient care while reducing reliance on pharmacological solutions. Nexalin is also gearing up for regulatory clearance in the U.S. and commercial expansion internationally.
Read more →NXL▲ +51.1%on this newsshared move
Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board
Nexalin Technology has appointed William A. Hudson, Jr. to its Military & Government Advisory Board. Hudson, a former Acting General Counsel for the Department of Veterans Affairs, brings extensive experience in military and federal law. His role will support Nexalin's efforts to advance non-invasive treatments for mental health issues among military personnel and veterans.
Read more →NXL▲ +51.1%on this newsshared move
Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board
Nexalin Technology, Inc. has appointed William A. Hudson, Jr., a veteran in government affairs and former Acting General Counsel of the Department of Veterans Affairs, to its Military & Government Advisory Board. Hudson brings significant experience in navigating military and governmental agencies, which Nexalin aims to leverage for advancing its non-invasive mental health treatment technologies. The company's products are designed to assist military personnel and veterans suffering from conditions such as PTSD, TBI, and depression. Hudson expressed enthusiasm for supporting Nexalin’s mission to provide effective, drug-free treatment alternatives.
Read more →NXL▲ +79.5%on this news· ran to +208% by day 3shared move
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
Nexalin Technology, Inc. announced positive results from a clinical study of its Gen-2 tACS device aimed at reducing pain in veterans with Mild Traumatic Brain Injury (mTBI). Conducted at the University of California, San Diego in collaboration with the VA, the study demonstrated significant reductions in post-concussive symptoms compared to a control group. The results were encouraging, indicating the device's potential to serve as a non-invasive alternative to medication for mTBI treatment. The company plans to present these findings at an upcoming BARDA meeting.
Read more →NXL▲ +20%on this news
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology
Nexalin Technology has launched sales of its Gen-2 neurostimulation device at a new mental health center in Oman, focusing on treating substance abuse disorders. The center received regulatory approval from Oman's Ministry of Health and aims to expand treatment to other mental health issues. CEO Mark White highlighted the significance of this launch as a validation of their drug-free therapy approach.
Read more →NXL▲ +20%on this newsshared move
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology
Nexalin Technology, Inc. has launched sales of its second-generation neurostimulation device at a newly opened mental health center in Oman dedicated to treating patients with substance abuse disorder. The establishment received regulatory approval from the Sultanate of Oman’s Ministry of Health, confirming compliance with quality standards. The company's CEO expressed optimism about the center's role as a model for mental health treatment across the Middle East and advocated for a paradigm shift away from pharmaceuticals. The device is designed to provide a drug-free therapy option, which could broaden the scope of mental health treatment options in the region.
Read more →NXL▲ +8.2%on this news· ran to +30% by day 1shared move
Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”
Nexalin Technology announced its participation in the 'State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment' where it presented its Gen-3 Halo Clarity device. This device is aimed at treating traumatic brain injury (TBI) and PTSD. The event highlighted the need for innovative non-invasive neuroassessment tools, with significant interest from government entities in addressing TBI among veterans.
Read more →NXL▲ +8.2%on this news· ran to +30% by day 1shared move
Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”
Nexalin Technology, Inc. announced its participation in a poster presentation at the recent 'State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment' in Washington, D.C. The presentation focused on validating their Gen-3 Halo Clarity device, which aims to treat traumatic brain injury (TBI) and other mental health conditions. The event was supported by the USAMRDC and BARDA, showcasing the need for advancements in non-invasive neuro-assessment technologies. CEO Mark White highlighted the positive response from attendees, indicating growing governmental interest in innovative therapeutic options for veterans and warfighters dealing with TBI.
Read more →NXL▲ +49.6%on this news
Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia
Nexalin Technology has reported positive results from a clinical study of its Gen-2 tACS device for chronic insomnia. Conducted on 120 adult participants, the study revealed clinically meaningful improvements in sleep quality and efficiency, particularly in older individuals. The findings, published in the Journal of Psychiatric Research, suggest that the non-invasive treatment could serve as an alternative to conventional pharmacological therapies, which often come with undesirable side effects. Mark White, CEO of Nexalin, expressed optimism about the device's potential and the ongoing commitment to addressing the global mental health crisis.
Read more →NXLNexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device
Nexalin Technology, Inc. has received regulatory approval from Oman's Ministry of Health for its Gen-2 neurostimulation device, marking the company's first approval outside of China. The approval is expected to facilitate Nexalin's entry into the Middle East market, as the company aims to establish commercial distribution agreements in Oman soon. CEO Mark White expressed confidence in the company's technology, emphasizing its potential to contribute to addressing mental health challenges globally. This approval is part of Nexalin's broader strategy to scale operations and enter new international markets.
Read more →NXLNexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System
Nexalin Technology has been awarded a key patent for its non-invasive deep-brain stimulation device, the Gen-3 system. This patent covers critical technology that enhances treatment options for mental health conditions. The device aims to provide painless stimulation to brain regions associated with various disorders, including depression and anxiety. Nexalin plans to expand its regulatory approvals and commercial rollout.
Read more →NXLNexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System
Nexalin Technology, Inc. announced the issuance of U.S. Patent No. 11,872,397 for its Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System, a non-invasive deep brain stimulation device. The patent, protecting key technological innovations until 2040, supports Nexalin's advancements in treatment for mental health conditions. The company's Gen-3 system aims to provide painless neural stimulation, with clinical studies suggesting its efficacy in treating disorders such as treatment-resistant depression and insomnia. Nexalin is focused on regulatory approvals to commercially launch its device in the U.S. and overseas markets.
Read more →NXL▲ +9.7%on this news
Nexalin Technology Unveils Next-Generation HALO™ Clarity
Nexalin Technology has launched the HALO™ Clarity, a next-generation neurostimulation device aimed at treating mental health disorders from home. Utilizing Deep Intracranial Frequency Stimulation (DIFS™), the device promises enhanced therapeutic responses without adverse effects. Clinical trials in China have shown significant benefits, and Nexalin plans to conduct further trials in the U.S. while consulting with the FDA.
Read more →NXL▲ +9.7%on this newsshared move
Nexalin Technology Unveils Next-Generation HALO™ Clarity
Nexalin Technology has launched its next-generation HALO™ Clarity device aimed at treating diverse mental health conditions such as Major Depressive Disorder and PTSD. The device employs Deep Intracranial Frequency Stimulation (DIFS™) technology, facilitating drug-free treatment from home while allowing physicians to monitor patients remotely. Nexalin plans to initiate clinical trials in the U.S. and is optimistic about expedited processes and reduced costs associated with home-use treatment. The company anticipates that this innovative approach will transform mental healthcare delivery significantly.
Read more →NXLNexalin Technology Reports Significant Positive Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device on Treatment-Resistant Depression
Nexalin Technology, Inc. has announced positive results from a clinical study on its second-generation neurostimulation device for treatment-resistant depression. Conducted at Xuanwu Hospital in Beijing, the study showed significant improvements in depressive symptoms among patients with no adverse events reported. Results were published in the peer-reviewed journal 'General Psychiatry', enhancing the credibility of the findings. This device represents a non-invasive, drug-free approach to treating mental health issues, aligning with a growing demand for alternative therapies.
Read more →NXL▲ +19.3%on this news
Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David Lasseter
Nexalin Technology has established a Military & Government Advisory Board to enhance the commercialization of its non-invasive deep-brain stimulation devices. Led by David Lasseter, a veteran in government affairs, the board aims to foster partnerships with U.S. government agencies. The initiative aligns with increasing federal budget allocations for mental health services, particularly for veterans.
Read more →NXL▲ +19.3%on this newsshared move
Nexalin Technology Announces Formation of New Military & Government Advisory Board to be Led by Government Affairs Veteran David Lasseter
Nexalin Technology has established a Military & Government Advisory Board aimed at advancing its deep-brain stimulation devices within U.S. government agencies. Led by David Lasseter, a veteran of government affairs, the board will guide the strategic direction and commercialization of the company's technology. This initiative comes as the federal budget for mental health services continues to rise, highlighting the growing need for effective treatments for military personnel and veterans suffering from conditions like PTSD and anxiety. Nexalin's devices are designed to be non-invasive and free of adverse side effects, offering potential new solutions for mental health care.
Read more →NXL▼ -28.9%on this news
Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin’s Neurostimulation Device to Penetrate Deep Brain Structures
Nexalin Technology announced the publication of a study in Molecular Psychiatry, demonstrating its non-invasive device's ability to stimulate deep brain regions. This research suggests potential treatments for neuropsychiatric disorders, marking a significant advancement in neural stimulation technology. The findings indicate deeper penetration capabilities compared to existing technologies, enhancing efficacy without side effects.
Read more →NXL▼ -28.9%on this newsshared move
Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin’s Neurostimulation Device to Penetrate Deep Brain Structures
Nexalin Technology has announced the publication of a groundbreaking study in the journal Molecular Psychiatry. The research provides evidence that Nexalin's non-invasive neurostimulation device can directly stimulate deep brain structures associated with mental health disorders. This validation suggests the potential for more effective treatments for conditions such as depression and anxiety, using deeper penetration than current technologies. The study positions Nexalin as a leader in non-invasive neural stimulation, addressing significant mental health challenges globally.
Read more →NXLNexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms
Nexalin Technology, Inc. announced positive results from a clinical study of its Gen-2 neurostimulation device for treating migraines. Conducted at the Vertigo Center of Zhengzhou University, the trial indicated significant reductions in migraine frequency and severity among participants, with no reported adverse events. The study's findings support the device's safety and potential efficacy, which may address the needs of patients seeking non-invasive treatment options as demand for mental health therapies increases. Furthermore, Nexalin's device has also shown promise in treating depression, indicating a broader therapeutic application.
Read more →NXLNexalin’s CEO Mark White to be Interviewed Live on “The Big Biz Show” Today at 3PM Eastern Time
Nexalin Technology, Inc. announced that CEO Mark White will be interviewed live on 'The Big Biz Show' on August 3, 2023. He plans to discuss the company's innovative neurostimulation devices designed for mental health and addiction treatment. The show will be broadcasted across multiple platforms, enhancing visibility for Nexalin's mission.
Read more →NXLNexalin’s CEO Mark White to be Interviewed Live on “The Big Biz Show” Today at 3PM Eastern Time
Nexalin Technology, Inc. announced that its CEO Mark White will be interviewed on 'The Big Biz Show' today at 3 PM ET. In the interview, White plans to discuss recent advancements and milestones for their innovative neurostimulation devices aimed at treating mental health and addiction disorders. The show's broad reach will include cable TV, streaming services, and radio in 175 countries, allowing Nexalin to promote its non-invasive medical technology to a global audience.
Read more →NXLNexalin Technology Announces New Public Sector Division to Capitalize on Opportunities to Serve U.S. Government Agencies
Nexalin Technology has launched a new division called Nexalin America to engage with U.S. government agencies such as the Department of Defense and Department of Veterans Affairs. This initiative aims to promote Nexalin's non-invasive deep-brain stimulation devices for treating mental health disorders. The division is led by Ryan Kane, who has extensive experience in government partnerships. The company believes its technology offers promising alternatives for veterans and active military personnel suffering from mental health conditions.
Read more →NXLNexalin Technology Announces Abstract Accepted for Presentation at 2023 Military Health System Research Symposium Validating the Potential of its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Mild Traumatic Brain Injury
Nexalin Technology, Inc. announced that its abstract related to a non-invasive, frequency-based deep-brain stimulation device for treating mild traumatic brain injury has been accepted for presentation at the 2023 Military Health System Research Symposium. The study utilized Magnetoencephalography to show improvements in veterans with combat-related mTBI, indicating reductions in neuronal hyperactivity. Importantly, no adverse effects were reported by the participants, suggesting a viable treatment option for mTBI without medication. The acceptance of this abstract further validates Nexalin’s ongoing commitment to enhancing mental health outcomes.
Read more →NXLTechnology, Inc.
Nexalin Technology, Inc. has formalized a joint venture with Wider Come Limited to advance the commercialization of its second-generation transcranial Alternating Current Stimulation (tACS) devices in the Asia Pacific region. The partnership involves conducting four clinical trials to evaluate treatments for insomnia, depression, and other mental health issues. Wider will fund the operations of the joint venture, and both companies will share ownership. Nexalin's devices have recently received approval in China, marking a significant step in expanding access to its neurostimulation technology.
Read more →NXL▲ +7.2%on this newsshared move
Nexalin Technology, Inc. and Wider Come Limited Announce Joint Venture Agreement to Advance Commercialization of Nexalin’s tACS Devices in the Asia Pacific Region
Nexalin Technology, Inc. has announced a joint venture with Wider Come Limited to enhance the commercialization of its second generation transcranial Alternating Current Stimulation devices in the Asia Pacific region. This collaboration will involve clinical trials aimed at treating insomnia, depression, and other conditions, with Wider funding the operations for the first year. The partnership is expected to leverage Wider's distribution network and industry expertise, particularly in China, to broaden Nexalin's market presence. Additionally, the initiative may yield valuable data to support future clinical activities outside of Asia.
Read more →NXL▼ -18%on this news
Nexalin Technology Provides 2022 Year-End Business Update
Nexalin Technology, Inc. provided a business update for the year ending December 31, 2022, highlighting advancements in their neurostimulation devices aimed at treating mental health disorders. The company is preparing to submit its Gen-2 and Gen-3 devices to the FDA while also seeking to address new indications such as substance use disorder and PTSD. Despite experiencing sales challenges in China due to the pandemic, Nexalin achieved revenue growth in 2022 and maintains a solid liquidity position to support its business plans moving forward.
Read more →NXLNexalin Technology Appoints Medical Device Veteran Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory
Nexalin Technology has appointed Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory, leveraging his 23 years of regulatory expertise in the medical device sector. His role will focus on accelerating FDA approvals for Nexalin's innovative neurostimulation devices, particularly the Gen-2 and Gen-3 models aimed at treating mental health disorders. The company believes these devices could significantly enhance healthcare outcomes with a non-invasive, drug-free approach. Nketiah's background includes experience in gaining international regulatory approvals and managing clinical operations.
Read more →NXLNexalin Technology Announces Publication of a White Paper Validating its tACS Device for the Treatment of Generalized Anxiety Disorder
The Second Xiangya Hospital of Central South University, China, reports positive patient results, including disappearance of all somatic anxiety symptoms and improved quality of sleep Treatment effect persisted after four months of follow-up HOUSTON, TX, Nov. 14, 2022 (GLOBE NE
Read more →NXL▼ -5.3%on this news· ran to -27% by day 3
Nexalin Technology, Inc. Announces Closing of $9.6 Million Initial Public Offering
HOUSTON, TEXAS, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) today announced the closing of its previously announced initial public offering of 2,315,000 units consisting of 2,315,000 shares of its common stock and 2,315,000 accompanyin
Read more →NXLNexalin Technology, Inc. Announces Pricing of $9.6 Million Initial Public Offering
HOUSTON, TEXAS, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) today announced the pricing of its initial public offering of 2,315,000 units consisting of 2,315,000 shares of its Common Stock and 2,315,000 accompanying warrants to purch
Read more →NXLNexalin Technology Demonstrates Success in the Treatment of Depression
TUSTIN, CA--(Marketwired - Nov 9, 2017) - Nexalin Technology is pleased to announce the initiation of clinical trials designed by the University of Pennsylvania to investigate the effectiveness of the Nexalin transcranial stimulation (TACS) for major depressive disorder. A subsi
Read more →NXLNexalin Technology May Be the Future of Opiate Addiction Treatment
TUSTIN, CA--(Marketwired - Nov 7, 2017) - President Trump declares the opioid epidemic "a National public health emergency." Trump goes on to say "that ending the epidemic will require the resolve of our entire country." As a result of President Trump's statements, focus on safe
Read more →Competitive Position
How NXL ranks across every disease it competes inCompetitive Position is a premium feature
See how NXL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial